Skip to main content
SpringerLink
Log in

Methotrexate

  • Chapter
  • First Online:
Pediatric Inflammatory Bowel Disease

  • 1105 Accesses

Abstract

Through a variety of mechanisms including folate-independent pathways, once weekly low-dose methotrexate, either oral or parenteral, has been demonstrated to exert immune-modifying effects. The currently published data shows the efficacy of methotrexate in Crohn’s disease, while well-designed clinical trial data in ulcerative colitis is just emerging. While there is robust prospective data in adult Crohn’s disease, the current data in pediatric patients is largely retrospective but consistently encouraging. Large pediatric registry data clearly demonstrates that the rate of use of methotrexate as the first line immune modulator in pediatric Crohn’s disease is on the rise as is its use in combination with anti-tumor necrosis factor (TNF) agents.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. de Souza HSP, Fiocchi C. Immunopathogenesis of IBD:current state of the art. Nat Rev Gastroenterol Hepatol. 2016;13:13–27.

    Article  PubMed  Google Scholar 

  2. Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 2012;61:1619–35.

    Article  CAS  PubMed  Google Scholar 

  3. Markowitz J, Hyams J, Mack D, et al. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn disease. Clin Gastroenterol Hepatol. 2006;4:1124–9.

    Article  CAS  PubMed  Google Scholar 

  4. Jacobstein DA, Mamula P, Markowitz JE, Leonard M, Baldassano RN. Predictors of immunomodulatory use as early therapy in pediatric Crohn disease. J Clin Gastroenterol. 2006;40:145–8.

    Article  CAS  PubMed  Google Scholar 

  5. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn disease. Gastroenterology. 2000;119:895–902.

    Article  CAS  PubMed  Google Scholar 

  6. Riello L, Talbotec C, Garnier-Lengline H, et al. Tolerance and efficacy of azathioprine in pediatric Crohn disease. Inflamm Bowel Dis. 2011;17:2138–43.

    Article  PubMed  Google Scholar 

  7. Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol. 2015;13:847–58.

    Article  CAS  PubMed  Google Scholar 

  8. Panaccione R. Methotrexate: lessons from rheumatology. Can J Gastroenterol. 2005;9:541–2.

    Article  Google Scholar 

  9. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn disease. The North American Crohn study group investigators. N Engl J Med. 1995;332:292–7.

    Article  CAS  PubMed  Google Scholar 

  10. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn disease. North American Crohn study group investigators. N Engl J Med. 2000;342:1627–32.

    Article  CAS  PubMed  Google Scholar 

  11. Scherkenbach LA, Stumpf JL. Methotrexate for the management of Crohn’s disease in children. Ann Pharmacother. 2016;50:60–9.

    Article  CAS  PubMed  Google Scholar 

  12. Chabner BA, Allegra CJ, Curt GA, et al. Antineoplastic agents. In: Hardman JG, Limbird LE, Molinoff PB, et al., editors. Goodman and Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996. p. 1243–7.

    Google Scholar 

  13. Shea B, Swinden MV, Ghogomu ET, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. J Rheumatol. 2014;41:1049–60.

    Article  CAS  PubMed  Google Scholar 

  14. Paillot R, Genestier L, Fournel S, et al. Activation-dependent lymphocyte apoptosis induced by methotrexate. Transplant Proc. 1998;30:2348–50.

    Article  CAS  PubMed  Google Scholar 

  15. Genestier L, Paillot R, Quemeneur L, et al. Mechanisms of action of methotrexate. Immunopharmacology. 2000;47:247–57.

    Article  CAS  PubMed  Google Scholar 

  16. Johnston A, Gudjonsson JE, Sigmundskottir H, et al. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation of adhesion molecules. Clin Immunol. 2005;114:154–63.

    Article  CAS  PubMed  Google Scholar 

  17. Cronstein BN. The mechanism of action of methotrexate. Rheum Dis Clin North Am. 1997;23:739–55.

    Article  CAS  PubMed  Google Scholar 

  18. van Dieren JM, Kuipers EJ, Samsom JN, Nieuwenhuis EE, van der Woude J. Revisiting the immunomodulators tacrolimus. Methotrexate, and mycophenolate mofetil: their mechanisms of action and role in the treatment of IBD. Inflamm Bowel Dis. 2006;12:311–27.

    Article  PubMed  Google Scholar 

  19. Schroder O, Stein J. Low dose methotrexate in inflammatory bowel disease: current status and future directions. Am J Gastroenterol. 2004;98:530–7.

    Article  Google Scholar 

  20. Ranganathan P. An update on methotrexate pharmacogenetics in rheumatoid arthritis. Pharmacogenomics. 2008;9:439–51.

    Article  CAS  PubMed  Google Scholar 

  21. Herrlinger KR, Cummings JR, Barnardo MC, Schwab M, Ahmad T, Jewell DP. The pharmacogenetics of methotrexate in inflammatory bowel disease. Pharmacogenet Genomics. 2005;15:705–11.

    Article  CAS  PubMed  Google Scholar 

  22. Ardizzone S, Bollani S, Manzionna G, et al. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn disease: a randomized, investigator-blind study. Dig Liver Dis. 2003;35:619–27.

    Article  CAS  PubMed  Google Scholar 

  23. Mate-Jimenez J, Hermida C, Canter-Perona J, et al. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000;12:1227–33.

    Article  CAS  PubMed  Google Scholar 

  24. Chande N, Wang Y, MacDonald JK, McDonald J. Methotrexate for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2014;(8): CD006618. doi:10.1002/14651858.CD006618.pub3.

    Google Scholar 

  25. Khan N, Abbas AM, Moehlen M, Balart L. Methotrexate in ulcerative colitis: a nationwide retrospective cohort from the Veterans Affairs Health Care System. Inflamm Bowel Dis. 2013;19:1379–83.

    Article  PubMed  Google Scholar 

  26. Turner D, Grossman AB, Rosh JR, Kugathasan S, Gilman AR, Baldassano R, Griffiths AM. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn disease. Am J Gastroenterol. 2007;102:2804–12.

    Article  CAS  PubMed  Google Scholar 

  27. Turner D, Doveh E, Cohen A, Wilson ML, Grossman AB, Rosh JR, Lu Y, Bousvaros A, Deslandres C, Noble A, Baldassano RN, Levine A, Lerner A, Wilson DC, Griffiths AM. Efficacy of oral methotrexate in paediatric Crohn’s disease: a multicentre propensity score study. Gut. 2015;64:1898–904.

    Article  CAS  PubMed  Google Scholar 

  28. Mack DR, Young R, Kaufman SS, Ramey L, Vanderhoof JA. Methotrexate in patients with Crohn disease after 6-mercaptopurine. J Pediatr. 1998;132:830–5.

    Article  CAS  PubMed  Google Scholar 

  29. Uhlen S, Belbouab R, Narebski K, et al. Efficacy of methotrexate in pediatric Crohn disease: a French multicenter study. Inflamm Bowel Dis. 2006;12:1053–7.

    Article  CAS  PubMed  Google Scholar 

  30. Boyle B, Mackner L, Ross C, Moses J, Kumar S, Crandall W. A single-center experience with methotrexate after thiopurine therapy in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2010;51:714–7.

    Article  CAS  PubMed  Google Scholar 

  31. Ravikumara M, Hinsberger A, Spray CH. Role of methotrexate in the management of Crohn disease. J Pediatr Gastroenterol Nutr. 2007;44:427–30.

    Article  CAS  PubMed  Google Scholar 

  32. Weiss B, Lerner A, Shapiro R, et al. Methotrexate treatment in pediatric Crohn disease patients intolerant or resistant to purine analogues. J Pediatr Gastroenterol Nutr. 2009;48:526–30.

    Article  CAS  PubMed  Google Scholar 

  33. Willot S, Noble A, Deslandres C. Methotrexate in the treatment of inflammatory bowel disease: an 8-year retrospective study in a Canadian pediatric IBD center. Inflamm Bowel Dis. 2011;17:2521–6.

    Article  PubMed  Google Scholar 

  34. Sunseri W, Hyams JS, Lerer T, et al. Retrospective cohort study of methotrexate use in the treatment of pediatric Crohn’s disease. Inflamm Bowel Dis. 2014;20:134–5.

    Article  Google Scholar 

  35. Haisma S-M, Lijftogt T, Kindermann A, et al. Methotrexate for maintaining remission in paediatric Crohn’s patients with prior failure or intolerance to thiopurines: a multicenter cohort study. J Crohns Colitis. 2015;9:305–11.

    Article  PubMed  Google Scholar 

  36. Feagan BG, McDonald JW, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s disease. Gastroenterology. 2014;146:681–8.

    Google Scholar 

  37. Narula N, Peyrin-Biroulet L, Colombel JF. Combination therapy with methotrexate in inflammatory bowel disease: time to COMMIT? Gastroenterology. 2014;146:608–11.

    Article  CAS  PubMed  Google Scholar 

  38. Grossi V, Lerer T, Griffiths A, et al. Concomitant use of immunomodulators affects the durability of infliximab therapy in children with Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13:1748–56.

    Google Scholar 

  39. Vahabnezhad E, Rabizadeh S, Dubinsky MC. A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:606–13.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Colman RJ, Rubin DT. Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease. J Crohns Colitis. 2015;9:312–7.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Kurnik D, Loebstein R, Fishbein E, Almog S, Halkin H, Bar-Meir S, Chowers Y. Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn disease. Aliment Pharmacol Ther. 2003;18:57–63.

    Article  CAS  PubMed  Google Scholar 

  42. Stephens MC, Baldassano RN, York A, Widemann B, Pitney AC, Jayaprakash N, Adamson PC. The bioavailability of oral methotrexate in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2005;40:445–9.

    Article  CAS  PubMed  Google Scholar 

  43. Balis FM, Mirro J, Reaman GH, et al. Pharmacokinetics of subcutaneous methotrexate. J Clin Oncol. 1988;6:1882–6.

    Article  CAS  PubMed  Google Scholar 

  44. Wilson A, Patel V, Chande N, Ponich T, Urquhart B, Asher L, Choi Y, Tirona R, Kim RB, Gregor JC. Pharmacokinetic profiles for oral and subcutaneous methotrexate in patients with Crohn’s disease. Aliment Pharmacol Ther. 2013;37:340–5.

    Article  CAS  PubMed  Google Scholar 

  45. Goodman SM, Cronstein BN, Bykerk VP. Outcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature review. Clin Exp Rheumatol. 2015;33:272–8.

    PubMed  Google Scholar 

  46. Ruemmele FM, Veresd G, Kolhoe KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis. 2014;8:1179–207.

    Article  CAS  PubMed  Google Scholar 

  47. Bulatovic M, Heijstek MW, Verkaaik M, et al. High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: development and validation of a methotrexate intolerance severity score. Arthritis Rheum. 2011;63:2007–13.

    Article  CAS  PubMed  Google Scholar 

  48. Kempinska A, Benchimol E, Mack A, Barkey J, Boland M, Mack DR. Short-course ondansetron for the prevention of methotrexate-induced nausea in children with Crohn disease. J Pediatr Gastroenterol Nutr. 2011;53:389–93.

    CAS  PubMed  Google Scholar 

  49. Lemann M, Zenjari T, Bouhnik Y, et al. Methotrexate in Crohn disease: long-term safety and toxicity. Am J Gastroenterol. 2000;95:1730–4.

    CAS  PubMed  Google Scholar 

  50. Graham LD, Myones BL, Rivas-Chacon RF, Pachman LM. Morbidity associated with long-term methotrexate therapy in juvenile rheumatoid arthritis. J Pediatr. 1992;120:468–73.

    Article  CAS  PubMed  Google Scholar 

  51. Chong RY, Hanauer SB, Cohen RD. Efficacy of parenteral methotrexate in refractory Crohn disease. Aliment Pharmacol Ther. 2001;15:35–44.

    Article  CAS  PubMed  Google Scholar 

  52. Batres LA, Gabriel CA, Tsou VM. Methotrexate-induced esophagitis in a child with crohn disease. J Pediatr Gastroenterol Nutr. 2003;37:514–6.

    Article  PubMed  Google Scholar 

  53. Roenigk Jr HH, Auerbach R, Maibach H, et al. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol. 1988;19:145–56.

    Article  PubMed  Google Scholar 

  54. Kremer JM, Alarcon GS, Lightfood Jr RW, et al. Methotrexate for rheumatoid arthritis. Suggested guideline for monitoring liver toxicity. Arthritis Rheum. 1994;37:316–28.

    Article  CAS  PubMed  Google Scholar 

  55. Kugathasan S, Newman AJ, Dahms BB, Boyle JT. Liver biopsy findings in patients with juvenile rheumatoid arthritis receiving long-term weekly methotrexate therapy. J Pediatr. 1996;128:149–51.

    Article  CAS  PubMed  Google Scholar 

  56. Khan N, Abbas AM, Whang N, Balart LA, Bazzano LA, Kelly TN. Incidence of liver toxicity in inflammatory bowel disease patients treated with methotrexate: a meta-analysis of clinical trials. Inflamm Bowel Dis. 2012;18:359–67.

    Article  PubMed  Google Scholar 

  57. Valentino PL, Church PC, Shah PS, Beyene J, Griffiths AM, Feldman BM, Kamath BM. Hepatotoxicity caused by methotrexate therapy in children with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014;20:47–59.

    Article  PubMed  Google Scholar 

  58. Laharie D, Zerbib F, Adhoute X, Boué-Lahorgue X, Foucher J, Castéra L, Rullier A, Bertet J, Couzigou P, Amouretti M, de Lédinghen V. Diagnosis of liver fibrosis by transient elastography (Fibro Scan) and non-invasive methods in Crohn’s disease patients treated with methotrexate. Aliment Pharmacol Ther. 2006;23:1621–8.

    Article  CAS  PubMed  Google Scholar 

  59. Rains CP, Noble S, Faulds D. Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs. 1995;50:137–56.

    Article  CAS  PubMed  Google Scholar 

  60. Conway R, Low C, Coughlan RJ, O’Donnell MJ, Carey JJ. Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials. BMJ. 2015;350:h1269.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pediatric Gastroenterology, Clinical Development and Research Affairs, Goryeb Children’s Hospital/Atlantic Health, 100 Madison Avenue, Morristown, NJ, 07962, USA

    Joel R. Rosh MD

  2. Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Joel R. Rosh MD

Authors
  1. Joel R. Rosh MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joel R. Rosh MD .

Editor information

Editors and Affiliations

  1. Division of GI, Hepatology & Nutrition, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

    Petar Mamula

  2. Division of GI, Hepatology & Nutrition, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

    Andrew B. Grossman

  3. Division of GI, Hepatology & Nutrition, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

    Robert N. Baldassano

  4. Division of GI, Hepatology & Nutrition, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

    Judith R. Kelsen

  5. Division of Pediatric Gastroenterology & Nutrition, University of South Carolina School of Medicine - Greenville, Greenville, South Carolina, USA

    Jonathan E. Markowitz

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Rosh, J.R. (2017). Methotrexate. In: Mamula, P., Grossman, A., Baldassano, R., Kelsen, J., Markowitz, J. (eds) Pediatric Inflammatory Bowel Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-49215-5_31

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-49215-5_31

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-49213-1

  • Online ISBN: 978-3-319-49215-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation